Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin

Table 1

Baseline characteristics of four D+/R− patients with confirmed ganciclovir-resistant CMV.

Patient number	Age/race/sex/weight (kg)	Donor type/PRA (%)	Induction	Time to 1st PCR (days)	1st PCR (copies)	SCr/GFR/CrCl at time of 1st PCR	Dose-adjusted for CrCl at time of 1st PCR (mg/day)	Peak PCR (copies)
1	28/AA/M/95	D/16	ATG	178	42807	2.2/43/53	900	42807
2	39/W/M/105	L/0	IL2-ra	90	1857	1.7/45/74	450	2257
3	32/AA/M/116	D/0	ATG	85	741	1.8/53/67	450	6240
4	32/AA/M/82	D/88	ATG	104	2987	1.5/65/73	450	2987

ATG: antithymocyte globulin; AA: African American; CrCl: creatinine clearance (mL/min); D: deceased donor; GFR: glomerular filtration rate (mL/min/1.73²); IL2-ra: interleukin 2 receptor antagonist; L: living donor; M: male; PCR: polymerase chain reaction; PRA: panel reactive antibodies; SCr: serum creatinine (mg/dL); W: White.